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Background: Cardiovascular risk largely depends on diet, antioxidant status and 
gene polymorphisms. Low-fat meat (CM) and walnut enriched meat (WM) products 
may exert potential beneficial health effects with respect to conventional meat products. 
Objective: To compare the effects of consuming WM vs. CM on reduced and 
oxidized glutathione, lipoperoxides, α- and γ-tocopherol levels and paraoxonase (PON-
1), catalase (CAT), superoxide dismutase (SOD) activities in 22 volunteers (mean 54.8 
years and BMI 29.6 kg/m2) at high cardiovascular risk carrying different PON-1 192/55 
polymorphisms.  
Design: The study was a 5-week non-blinded, randomized, cross-over, controlled 
trial. 
Results: In general term, WM vs. CM improved the volunteers’ antioxidant status 
with several result modifications occurring after WM period. CM consumption 
increased oxidized glutathione and decreased PON-1 activity (at least P < 0.05). When 
WM vs. CM effects were compared SOD, CAT and PON-1 enzyme activities increased 
(at least P < 0.05) in PON-1 192QQ carriers. γ-tocopherol levels, SOD and PON-1 
activities increased in PON-1 192QR+RR carriers besides the significant decrease of 
lipoperoxide levels. In PON-1 55LM+MM carriers, the intervention increased 
significantly all the investigated enzyme activities and glutathione levels while PON-1 
55LL carriers increased their PON-1 activities.  
Conclusions: WM consumption should be preferred to CM. The intake of WM vs. 
CM increased PON-1 but the effect upon other antioxidant enzymes and substrates 
varied depending on individual’s PON-1 polymorphism. PON-1 192QR+RR carriers 
appear the targets for WM consumption as increased the enzyme activities and γ-
tocopherol levels and decreased lipoperoxides. 
 
Abbreviations: CHD = Coronary heart diseases; CM = Low-fat control meat; WM = 
Walnut paste-enriched meat, CAT = Catalase, LPO = lipoperoxides, SOD = Superoxide 
dismutase, GSH = Reduced glutathione, GSSG = Oxidised glutathione, PON-1 = 
Paraoxonase. 
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Nut/tree nut consumption has been associated with decreased risk factors for coronary 
heart diseases (CHD) and Metabolic Syndrome (MS) [1]. Walnuts and other nut species 
present a favorable fatty acid profile [2] and contain several of bioactive compounds 
that are coupled with other nutrients such as vitamin E, vitamin C, selenium and act as 
antioxidants and anti-inflammatory factors [3-5]. Meat and meat products are essential 
components of diets in Western countries. In Spain, their average consumption is high 
(ca. 164 g/head and day) [6]. As epidemiological findings have related high-fat meat 
consumption to degenerative disease [7], efforts have been made to obtain low-fat meat 
and meat products. Restructured beef steaks and/or sausages formulated with walnut 
paste (WM) provide a unique combination of nutrients and phytochemicals [8] and 
display acceptable physiochemical and sensory properties [9]. Our research group 
previously found that volunteers at high risk of developing CHD who consumed walnut 
paste-enriched meat (WM) presented more favorable antioxidant status - measured as 
catalase (CAT), superoxide dismutase (SOD), and paraoxonase-1 (PON-1) activities, 
reduced (GSH) and oxidized glutathione (GSSG) levels in erythrocytes [10] and γ-
tocopherol [11] and thrombogenic profiles [12] than those consuming low-fat meat 
(CM). However, data showed striking interindividual differences probably due to 
genetics.  
Human paraoxonase (PON-1), a HDL-bound enzyme, is a pleiotropic enzyme 
involved in the protection against oxidative damage and detoxification of reactive 
molecules and/or xenobiotics [13-15]. More specifically, this enzyme is engaged in 
lipoprotein-phospholipid metabolism and may also inhibit lipid peroxide generation in 
LDL [7, 16,17]. When lipid peroxidation occurs in LDL, one of the first enzymes acting 
in order to preserve LDL and protect them against oxidation is PON-1 [18]. However, 
PON-1 can be inactivated by oxidative stress and oxidized lipids [19]. Martinelli et al. 
[20] hypothesized that a greater degree of severity of MS is associated with an increased 
oxidative stress which inactivates PON-1 function. 
Despite current interest in this enzyme and numerous studies investigating its 
behavior, little is yet certain with regard to its biological function or the activity of its 
polymorphisms. PON-1 exists in two major polymorphic forms which include the 
replacement of glutamine (Q) by arginine (R) at position 192 [21], and that of leucine 
(L) by methionine (M) at position 55 [22]. Polymorphisms at 55 and 192 positions are 
associated with a 40-fold interindividual variability in PON-1 enzyme activity [23]. The 
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PON-1-192 polymorphism is associated with diminished PON-1 concentrations and an 
increased risk for CHD in RR-allele subjects [24]. It has been reported that PON-1 in 
HDL particles of 192R allele carriers offers significantly less protection against LDL 
peroxidation in vitro than in case of 192Q and 55L carriers [18]. Our group has 
analyzed the response of carriers of the major PON-1 polymorphisms to WM and CM 
with reference to arylesterase activity and lipoperoxides (LPO) [25] and other 
biomarkers for CHD, including PON-1, soluble vascular and intercellular adhesion 
molecules (sVCAM-1 and sICAM-1) and leukotriene B4 (LTB4) levels [26]. The 
positive effect of WM consumption was largely influenced by PON 1 polymorphisms 
[25,26]. 
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Taking into account previous cited studies, the hypothesis of the present study is 
that WM is more effective than CM in reducing the in vivo oxidative stress in the 
erythrocytes of individuals at high risk for developing CHD with certain PON-1 gene 
alleles. Thus, the present trial aimed to analyze the effects of a 5-week consumption of 
WM and CM in volunteers carrying PON-1 55 and/or 192 polymorphisms on a) serum 
α-tocopherol and γ-tocopherol levels and PON-1 activity; b) erythrocyte reduced 
glutathione (GSH), oxidized glutathione (GSSG), and LPO concentrations and SOD and 
CAT activities. 
 
2. Subjects and methods 
2.1. Subjects 
Eligibility and exclusion criteria have been already published [10,11]. Briefly, 
eligibility criteria for the study included a) age of men ≥45 years; age of women ≥50 
years and postmenopausal, and b) BMI ≥25-<35 kg/m2. In addition, one or more of the 
following criteria also had to be met: serum total cholesterol ≥5.69 mmol/l; smoking 
habit (≥10 cigarettes per day); hypertension (systolic pressure ≥140 mmHg and/or 
diastolic pressure ≥90 mmHg). Subjects had to be frequent meat product consumers (≥ 5 
times/week). Exclusion criteria of the study included: a) familial hypercholesterolemia 
IIa and/or type I and II diabetes; b) use of vitamin or mineral supplements; c) hormone 
replacement therapy; d) regular use of aspirin and medications known to affect lipid 
absorption or metabolism and any chronic disease (e.g. antidiabetic, antiaggregant 
drugs); e) non-frequent meat products consumption (< 5 times/week). Four individuals 
taking medication for hypertension were initially excluded, but given the small number 
of subjects willing to participate, it was necessary to include them. Of the 144 
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candidates initially recruited through announcements in the media and in hospitals, 
twenty-five volunteers were finally chosen and started the trial. Three volunteers who 
did not complete the requisite blood extractions were also excluded from the trial; thus, 
twenty two volunteers, 12 males and 10 females, completed the intervention.  
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Procedures followed were in accordance with the standards of the Ethics Committee 
of the University Hospital of Puerta de Hierro (Madrid, Spain) and the Helsinki 
Declaration, as indicated in the guidelines of the Scientific Technologic Project AGL 
2001-2398-C03. Informed consent was given by the participants prior to the start of the 
study.  
 
2.2. Study Design 
Volunteers were randomly assigned to follow a non-blinded, cross-over, controlled 
study, consisting of two 5-week experimental periods. The study design has been 
described previously [11], shortly participants followed their normal dietary habits 
during the 4 to 6-week wash-out interval that separated the two trial periods. During the 
WM period, volunteers consumed four 150 g restructured WM steaks and a 150 g ration 
of WM sausages per week, all containing 20% walnut paste. During the CM period, 
volunteers consumed four 150 g restructured CM steaks and a 150 g ration of CM 
sausages each week. The composition of the two types of meat studied is presented in 
Table 1. Information regarding the preparation of meat products (WM and LM) is 
available in Serrano et al. [9]. Study participants were strongly advised to avoid 
consuming any other meats or meat products in their diet during the trials.  
 
2.3. Dietary assessment  
Frozen CM and WM products were distributed to study participants on a weekly 
basis. Special emphasis was given to compliance and management of intake with regard 
to frequency, dates and numbers of steaks consumed. The substitution of conventional 
meat products by the experimental meat products in the framework of a mixed diet was 
confirmed and verified by regularly checking the volunteers’ dietary records. 
Participants recorded the amount and kinds of food eaten every day to avoid any 
possible doubt regarding their diets. Food Composition Tables [27] were used to 
calculate the volunteers’ dietary energy and nutrient intakes. Despite the peculiar taste 
of WM, most volunteers (80%) reported enjoying this type of meat. Forty percent of the 
participants, however, commented unfavorably on the low palatability of CM. In 
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addition, walnuts provide γ-tocopherol, which was used as a marker to assess 
compliance by measuring volunteers serum concentrations after each trial period 
[10,11]. 
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2.4. Sample collection and Preparation of hemolyzates 
Blood samples were collected and prepared for analysis by trained staff. Blood was 
gently delivered in vacutainer tubes for PON-1 determinations while in citrate tubes for 
SOD, CAST, GSH and GSSG analysis. Serum was separated at 1500 x g for 15 min at 
4ºC while citrated blood was centrifuged at 1000 x g for 10 min at 4ºC, and the plasma 
and buffy coat removed. Erythrocytes were washed with PBS (pH 7.00, containing 140 
mM NaCl) three times and erythrocytes were hemolyzed with ice-cold distilled water. 
Hemoglobin (Hb) content was determined by using the cyanmethemoglobin method 
[28]. Hemolyzates were used to determine SOD and CAT enzymatic activities and GSH 
and GSSG concentrations.  
 
2.5. Enzymes assays 
SOD activity (EC 1.15.11) was determined according to Marklund & Marklund 
method [29], based on pyrogallol autoxidation. One unit of enzyme activity was defined 
as 50% inhibition of the rate of pyrogallol autoxidation. Results were expressed as U/g 
Hb. CAT (EC 1.11.1.6) activity was estimated according to Aebi method [30], 
monitoring the rate of disappearance of hydrogen peroxide at 240 nm. CAT activity was 
expressed as U/g Hb. PON-1 (EC 3.1.8.1) activity was determined in Tris/HCL buffer 
(90mM Tris/HCl, 3.6mM NaCl and1.9mM CaCl2) by measuring the rate of hydrolysis 
of paraoxon in p-nitrophenol catalyzed by the enzyme at 37ºC and 405nm [31]. Frozen 
aliquots of pool sera were used as the internal control. One unit of PON-1 activity was 
defined as 1 μmol of p-nitrophenol formed per L per minute in sera. 
 
2.6. Glutathione status and Lipid Peroxide assay 
Total glutathione (GSH plus GSSG) was measured by fluorometry, according to 
Hissin & Hilf method [32], using o-phthaldialdehyde. GSH and GSSG results were 
expressed as μmol/g Hb. The redox index was calculated as the GSH/GSSG ratio. 
Measurements of LPO in erythrocytes, based on determination of malonyldialdehyde 
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(MDA) and 4 hydroxyalkenals, was performed using the Bioxytech LPO-586 kit (Oxis 
Research, Porland, USA). 
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2.7. α-tocopherol and γ-tocopherol assays.  
α-tocopherol and γ-tocopherol in the serum of the volunteers were analyzed by 
means of high performance liquid chromatography (HPLC). Methodological details 
have been described elsewhere [11]. The HPLC method was validated throughout our 
participation in the Fat-soluble Vitamins Quality Assurance Programme (for serum and 
food samples) conducted by the National Institute of Standard and Technology (NIST, 
USA). End data for α-tocopherol and γ-tocopherol correspond to the mean of analyses 
on days 28 and 35 in each meat period. 
 
2.8. Serum lipids and glucose.  
Serum cholesterol, HDL cholesterol and triglycerides were determined by standard 
enzymatic analysis (Boehringer, Manheim, Germany). Cholesterol transported by LDL 
was calculated using the Friedewald et al formula, where LDL cholesterol = Total 
cholesterol – (HDL cholesterol + Triglycerides /5), all parameters in mg/dl. 
 
2.9. Paraoxonase genotyping  
DNA was extracted from peripheral blood cells using the Ultraclean Bloodspin kit 
(MoBio Laboratories Inc, Carlsbad, California, USA). PON-1 genotyping was carried 
out by a multiplex PCR assay [33]. Amplification of 111 and 144 pb fragments was 
performed using a standard polymerase chain reaction (PCR) for PON-1-Q192R and 
PON-1-L55M, respectively. Reagents were purchased from Promega (Madison, USA) 
and PCR was performed using a DNA thermocycler (Mastercycler-ep380®, Eppendorf, 
Hamburg, Germany).  
 
2.10. Statistical Analyses 
Data are presented as means ± SD. The Kolmogorov-Smirnov test was used to test 
for the normal distribution of data. Although the study was designed having serum 
cholesterol as the primary outcome variable, the present paper displayed a statistical 
power higher than 85% to detect a 30% relative difference (15 U/L) between the 
responses in PON-1 activity of volunteers who consumed the two different meats, 
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considering an alpha level of 0.05. A pooled SD of 25% (12 U/L) for the change from 
baseline PON-1 activity was assumed for this calculation. The statistical power for 
individuals with different PON-1 polymorphisms (group comparison of 11 vs. 11 or 8 
vs. 14) was 79% and 76%, respectively. Repeated measures analysis of variance was 
used to compare the effect of WM vs. CM on the variables studied in carriers of each 
PON-1 allele. A post hoc study was performed in each polymorphism by repeated 
measures analysis of variance. The net change (%) mean and 95%CI for each variable 
was calculated taken into account end and baseline of both periods as follow: 
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Net change (%) = (WMend-WMbaseline)-(CMend-CMbaseline)*100/CMbaseline  
 
3. Results 
From the twenty two participants, 12 were males and 10 females. The average age 
of them was 54.8 years with no-significant age gender differences (p>0.1). Mean BMI 
was 29.6 kg/m2 (55% overweight and 45% obese). Genotype frequencies at both 
restriction enzyme sites (55 and 192) were in Hardy-Weinberg equilibrium (p > 0.05).  
Table 2 shows the daily intake of macronutrients, fiber, and cholesterol during both 
experimental periods in PON-1 192QQ and QR+RR carriers and in PON-155 LL and 
LM-MM carriers, respectively. Volunteers followed isocaloric diets during both 
intervention periods. The significant differences found in energy and macronutrient 
intakes during WM and CM periods involved fat, PUFA, SFA, total tocopherol and the 
omega-6/omega-3 ratio. No significant differences were found between QQ and 
QR+RR carriers and between LL and LM+MM carriers. Table 3 shows some 
anthropometrical and clinical data of volunteers carrying the PON-1 192 and PON-1 55 
polymorphisms during both study periods. The level of triglycerides were differently 
affected (p=0.024) in PON-1 192QQ vs. QR+RR carriers. Triglycerides, the systolic and 
diastolic blood pressures were differently affected (at least p=0.033) in PON-1 55LL vs. 
LM+MM. The net effect of the intervention (WM vs. CM) only affected the diastolic 
pressure in PON-1 192QQ and QR + RR carriers, although some significant effects 
were observed for total cholesterol (PON-1 192QR +RR), HDL cholesterol (PON-1 192 
QQ), diastolic blood pressure (PON-1 192QQ) during the CM period and for HDL 
cholesterol (PON-1 55LM+MM), systolic and diastolic blood pressures (PON-1 
192QR+RR and PON-1 55LL) during the WM period.  
In the volunteers, and without considering polymorphisms, a significant net increase 
(% mean, 95%CI) of CAT (28.5, 8.1 to 49.0 U/g Hb), SOD (16.7, 4.6 to 28.7 U/g Hb) 
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and PON-1 (62.2, 31.8 to 100.5 U/L) activities was obtained by the global intervention 
(WM vs. CM) (data not shown). CAT, SOD, and PON-1 activities and GSH, GSSG, 
and γ-tocopherol levels increased significantly (p < 0.05) in the total of the 22 
volunteers after 5 weeks of consumption of WM diet but not in CM diet. PON-1 activity 
decreased (p < 0.05) following CM diet period. Thus, results following the WM were 
not strictly similar to those found after the WM vs. CM comparison (data not shown).  
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The redox index (p = 0.044) and LPO concentrations (p = 0.045) were affected by 
the PON-1 192 genotype*treatment interaction (Table 4). In comparison to CM, WM 
increased GSH (p = 0.046) and GSSG (p = 0.001) levels in PON-1 192QQ while in 
QR+RR carriers increased γ-tocopherol levels (p = 0.037) and decreases LPO levels (p 
= 0.009) (Table 4). WM vs. CM consumption leads to an increase of CAT (p = 0.014), 
SOD (p = 0.029), PON-1 (p = 0.001) and PON-1/HDL cholesterol (p = 0.05) activities 
in PON-1 192QQ while in QR+RR carriers increased SOD (p = 0.015), PON-1 (p = 
0.037) and PON-1/HDL cholesterol (p = 0.045) activities (Table 5).  
In PON-1 192QQ carriers consuming WM, CAT (p < 0.01), SOD (p < 0.001), and 
PON-1 (p < 0.01) and PON-1/HDL cholesterol (p< 0.05) activities and levels of GSH 
(p < 0.01) GSSG (p < 0.001) and γ-tocopherol levels (p < 0.05) increased significantly, 
while the redox index (p < 0.05) decreased. In PON-1 192QR+RR carriers consuming 
WM, LPO values (p < 0.01) significantly decreased, while GSH (p < 0.05), GSSG (p < 
0.001) and γ-tocopherol (p < 0.05) levels increased. In PON-1 192 QQ carriers 
consuming CM, GSSG values (p < 0.01) increased significantly while PON-1 activity 
decreased (p < 0.05) (Tables 4 and 5). In PON-1 192QR+RR, CM decreased PON-1 
activity (p < 0.05) (Tables 4 and 5).  
A significant interaction between the PON-1 55 polymorphism and meat type was 
found for GSH levels (p = 0.047) (Table 4). In comparison to CM, WM increased GSH 
(p = 0.001) and GSSG (p = 0.001) levels in PON-1 55 LM+MM (Table 4). WM vs. CM 
consumption increased CAT (p = 0.007), SOD (p = 0.003), PON-1 (p = 0.009) and 
PON-1/HDL cholesterol (p=0.048) activities while in LL carriers increased PON-1 (p = 
0.002) activities (Table 5).  
In PON-1 55LL carriers, WM intake increased SOD (p < 0.05) and PON-1 (p < 
0.05) and PON-1/HDL cholesterol (p< 0.05) activities and GSSG (p < 0.01) and γ-
tocopherol levels (p < 0.05) levels. In PON-1 55LM+MM carriers, WM consumption 
increased CAT (p < 0.01), SOD (p < 0.01), PON-1 (p < 0.05) and PON-1/HDL 
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cholesterol (p<0.05) activities and GSH (p < 0.001), GSSG (p < 0.001) and γ-
tocopherol (p < 0.05) levels. In PON-1 55LL, the CM intake increased GSH levels (p < 
0.05) but decreased PON-1 activity (p < 0.05). In PON-1 55 LM+MM, the CM intake 
increased GSSG levels (p < 0.05) and decreased the PON-1 activity (p < 0.05) (Tables 4 
and 5).  
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When the net nutritional effects on the antioxidant status in volunteers 
presenting concurrence of both PON-1 192 and 55 polymorphisms were tested, increase 
in CAT (p = 0.004), SOD (p = 0.002), GSH (p = 0.020), GSSG (p = 0.004), and PON-1 
(p = 0.012) were observed in (LM+MM)QQ carriers while only significant increase was 
observed in PON-1 activity in LL(QR+RR) counterparts (data not shown). CM 
significantly increased concentrations of GSH (p < 0.05) in LL (QR+RR) and those of 
GSSG (p < 0.05) in (LM+MM, QQ) carriers. WM did not increase any antioxidant 
parameters except GSSG levels (p < 0.01) in LL(QR+RR) individuals, but it increased 
CAT (p < 0.01), SOD (p<0.01), GSH (p < 0.01), GSSG (p = 0.001), and PON-1 activity 
(p < 0.05) and decreased the redox index (p < 0.05) in (LM+MM),QQ carriers (data not 
shown). 
 
4. Discussion 
This is the first study to date that evaluates the effects of two potential functional 
meat products, WM and CM, on several antioxidant status markers in volunteers at high 
risk of developing CHD carrying different PON-1 polymorphisms. Despite the 
relatively low number of individuals studied for each polymorphism, the present paper 
provides new data regarding differences in response of PON-1 192QQ vs. 192QR+RR 
and PON-1 55LL vs. LM+MM carriers and in volunteers carrying PON-1 192 and 
PON-1 55 polymorphisms. 
No significant differences were observed in energy consumed by volunteers during 
the WM and CM diets period; although the former diet was somewhat richer in energy 
than the latter, as it contributed a greater amount of fat and polyunsaturated fatty acids. 
In addition to their high ω-6 and ω-3 polyunsaturated fatty acid content [3-5, 34], 
walnuts also contain compounds such as arginine, γ-tocopherol and polyphenols [4,34] 
that improve antioxidant status and may be associated with decreased prevalence of 
CHD [1,2,13] and MS risk factors [1].  
No significant differences in energy and macronutrient energy intakes were found 
between PON-1 192QQ vs. QR+RR and between PON-1 55LL vs. LM+MM allele 
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carriers through the study; thus, results have to be related to differences in response to 
diet of volunteers due to their respective PON-1 192 and/or PON-1 55 polymorphisms. 
Basal data on lipids and blood pressures suggest, in general terms, that PON-1 192QQ 
and PON-1 55LM+MM showed lower CHD risk than their QR+RR and LL respective 
counterparts. These results agree with the available information on PON-1 
polymorphisms and CHD risk [13,18]. The differences in PON-1 basal activities found 
by Mackness et al. [35] between QQ and QR/RR carriers were not observed in the 
present paper. Although no clear explanation is available, the tendency to consume 
higher PUFA and tocopherol amounts by QQ carriers, would explain, at least partially, 
such values, as PUFA consumption has been related to PON-1 activity [13]. Oliveira et 
al. [36] found that the M allele was more prevalent among control subjects than in CHD 
patients; however, in a meta-analysis study, Wheeler et al. [37] reported no significant 
association between the PON-1 55 polymorphisms and CHD. The effect of WM and 
CM diets on blood pressure were noticeable during the whole trial. The dietary increase 
of nuts and/or the reduction of saturated fat is known to positively affect blood pressure 
[1,34,38]. Only QR+RR and LL significantly decreased both systolic and diastolic 
blood pressures during the WM period. In addition, only QQ decreased significantly 
diastolic blood pressure during the CM period, suggesting clear differences in response 
to those meat derivates in PON-1 polymorphism carriers.  
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In the totally of volunteers the WM vs. CM consumption in all the volunteers 
improved the antioxidant status. Interestingly, PON-1 activity during the WM period 
increased in all volunteers, except in PON-1 192QR+RR carriers, while it decrease in 
all of the volunteers during the CM period. The consumption of ω-3 polyunsaturated 
fatty acids has been found to increase PON-1 activity [39]. In the CM period, decrease 
in the PON-1 seemed to be parallel with the changes of HDL cholesterol. The reduction 
of dietary fat has been related to decrease in HDL [40] that may have resulted in the 
decrease of PON-1 enzyme activity associate to HDL particles. However, other 
compounds present in food, walnut and/or WM, e.g. polyphenols, could affect PON-1 
results [41,42]. Rantala et al. [43] reported decrease in PON-1 activity in women after 
the consumption of vegetable rich diet for 5 weeks. Strunz et al. [44] found that Brazil 
nuts affect PON-1 while Nus et al. [25] observed increase in the arylesterase activity 
after walnut enriched-meat consumption. As volunteers maintained their food habits 
throughout the whole study, an average reduction of about 8.5 g/day in the fat 
consumed and an increase in the intake of about 4 g polyunsaturated fatty acids could be 
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calculated with respect to their regular diet after the CM and WM, respectively, which 
might explain, at least partially, the change in PON-1 activity.  
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The PON-1 192 polymorphism has been associated with diminished PON-1 
activities and an increased risk for CHD in RR-allele subjects [24]. No significant 
baseline differences between QQ or R or between LL and M allele carriers in PON-1 
and other antioxidant enzymes and substrates were observed in either of the two dietary 
periods. Differences in the study design and type of volunteers tested would explain, at 
least partially, these discrepancies. QQ vs. QR+RR or LL vs. LM+MM carriers did not 
show significant differences in the PON-1 activity standardized for HDL cholesterol; 
however, QQ and LM+MM carriers tended to present the highest values for that ratio 
while QR+RR and LL carriers the lowest. Changes in the PON-1 activities during the 
WM period cannot be attributed to HDL cholesterol changes as the PON-1/HDL 
cholesterol ratio tended to increase both in PON-1 192 and 55 polymorphisms. 
Tocopherols are known to efficiently protect erythrocyte from lipid peroxidation 
[45]. According to present LPO and GSSG results, R carriers responded to WM vs. CM 
more efficiently than QQ carriers. These findings are important considering the higher 
CHD risk of R carriers [13,18]. Moreover, dietary γ-tocopherol in 192QR+RR increased 
significantly serum γ-tocopherol but not in QQ counterparts or in PON-1 55 carriers 
after the trial (WM vs. CM) explaining, at least in part, the decrease in erythrocyte LPO 
observed in R carriers. As far as we know this is the first report suggesting that the 
influence of diet on γ-tocopherol levels might be dependent of PON-1 allele; however, 
this conclusion has to be carefully interpreted due to the low number of volunteers 
tested in the study. Differences in tocopherol absorption and metabolization in the 
various PON-1 polymorphisms cannot be ruled out. Bub et al [24] found reduced lipid 
peroxidation and improved antioxidant status in R-allele-carriers but not in QQ 
homozygous elderly subjects on a tomato-rich diet. Davies et al. [46] suggested that 
paraoxon PON-1 activity was greatest in R allele carriers but Akçay et al. [47] found 
that R isoform carriers are less able to prevent accumulation of lipid peroxides in HDL 
and to protect LDL cholesterol from oxidation than Q allele carriers.  
Sözmen et al. [48] explain the increase in CAT and SOD activities observed in their 
study as a compensatory induction of these enzymes to oxidative stress. In fact, certain 
substrates are thought to promote the so-called “hormesis” property, by which a 
relatively low degree of peroxidation induces a strong antioxidant defense response 
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[49]. Barbosa et al. [50] justified a positive relation between ox-LDL and GPx activity 
by compensatory induction of the activity of this antioxidant enzyme. However, it has to 
be pointed out that ox-LDL were measured by Barbosa et al. [49] in plasma while in the 
present paper LPO were tested in erythrocytes. 
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In the presently studied polymorphisms, as a consequence of LPO and/or GSSG 
changes, various modifications in the antioxidant enzyme activity and in GSH were 
observed. A detailed study of data shows that the GSSG levels were significantly 
increased in PON-1 192QQ and in PON-1 55LM+MM volunteers suggesting, at least in 
part, that the significant increase observed in PON-1, SOD, and GSH in those carriers 
were related to an efficient “hormesis” property. In QR+RR volunteers less oxidation 
was obtained, thus increases in CAT were not found. On the other hand, in PON-1 
55LL carriers, no other change than in PON-1 activity due to the WM vs. CM 
consumption was observed suggesting that the “hormesis” effect was not totally 
required as the LPO and glutathione system were not significantly affected. WM and 
CM consumption affected LM+MM,QQ carriers and LL(QR+RR) individuals to similar 
degree as previously discussed in QQ and LM+MM individuals, suggesting that the 
results were not clearly influenced by the concurrence of PON-1 55/192 
polymorphisms.  
In summary, according to the present results, the consumption of WM should be 
preferred to that of CM. Although the intake of WM vs. CM increased PON-1 and other 
antioxidant enzymes in volunteers at high CHD risk, this response varied depending on 
each individual’s PON-1 polymorphism. According to LPO and γ-tocopherol, and 
antioxidant enzyme changes, subjects carrying the PON-1 192QR+RR appear to be 
target for WM vs. CM consumption. Future studies are required to better understand the 
influence of PON-1 polymorphisms on the antioxidant effect of WM consumption. 
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Table 1. Proximate composition and energy content of control meat and walnut paste-
enriched meat. 
 
Characteristics Control  
meat1 
Walnut paste-
enriched meat1 
Moisture (g/100g meat) 74.7 61.1 
Energy (kJ/100g meat) 403.4 873.6 
Protein (g/100g meat) 20.6 19.5 
Fat (g/100g meat) 1.6 14.5 
Ash (g/100g meat) 3.1 3.2 
SFA (g/100g total fatty acids) 42.1 11.2 
MUFA (g/100g total fatty acids) 38.0 13.7 
PUFA (g/100g total fatty acids) 19.8 74.9 
n-6/n-3 ratio 10.2 3.8 
Lysine/arginine ratio 1.3 1.1 
α-tocopherol (mg/100g meat) 0.1 0.2 
γ-tocopherol (mg/100g meat) 0.01 4.1 
δ-tocopherol (mg/100g meat) nd 0.8 
Magnesium (mg/100g meat) 20.2 41.4 
 
1corresponds to restructured steaks and sausages. SFA saturated fatty acids; MUFA 
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; nd, not detected. 
Adapted from Serrano et al. [10]. 
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Table 2. Daily energy intake, macronutrients and fatty acid energy contribution during walnut paste-enriched meat (WM), low-fat meat (CM) periods and 
the whole trial of participants according to their PON-1 192QQ and QR+RR and PON-1 55LL and LM+MM polymorphism variants. 
  WM CM Net change (%) 
Mean (95%CI) 
Net change (%) 
(p) Gen effect (p) 
QQ (11) 8104 ± 1138 7654 ± 1371 8.9 (-6.5 to 24.5) 0.230 R1 0.068 
QR+RR (11) 7261 ± 1264 7136 ± 956 2.3 (-8.9 to 13.6) 0.653  
LL (8) 7265 ± 1540 7289± 816 -0.4 (-14.5 to 13.6) 0.948 M1 0.238 
Energy  
(kJ) 
LM+MM (14) 7981 ± 1011 7943 ± 1400 9.6 (-3.4 to 22.6) 0.135  
QQ (11) 32.1 ± 7.6 30.5 ± 4.8 10.5 (-8.4 to 29.4) 0.247 R1 0.584 
QR+RR (11) 27.7 ± 8.1 36.1 ± 4.7 -23.5 (-37.6 to -9.5) 0.004  
LL (8) 29.5 ± 7.5 33.9 ± 8.4 -8.6 (-37.7 to 20.4) 0506 M1 0.804 
Carbohydrates  
(% En) 
LM+MM (14) 30.5 ± 8.4 32.8 ± 3.6 -2.9 (-19.8 to 13.8) 0.716  
QQ (11) 17.6 ± 2.3 18.6 ± 3.5 -1.6 (-17.6 to 14.5) 0.834 R1 0.513 
QR+RR (11) 19.4 ± 3.8 19.8 ± 3.1 -0.1 (-16.2 to 15.9) 0.984  
LL (8) 18.8 ± 3.8 19.4 ± 3.9 -0.9 (-18.5 to 16.7) 0.908 M1 0.572 
Protein  
(% En) 
LM+MM (14) 18.2 ± 2.8 18.9 ± 3.0 -0.9 (-15.7 to 13.8) 0.893  
QQ (11) 46.2 ± 1.8 44.2 ± 6.9 6.0 (0.9 to 5.1)* 0.135 R1 0.352 
QR+RR (11) 48.6 ± 9.1 40.9 ± 7.1 23.5 (14.1 to 32.4)*** 0.008  
LL (8) 48.3 ± 8.8 44.1 ± 10.3 9.5 (1.0 to 17.5)* 0.062 M1 0.791 
Fat  
(% En) 
LM+MM (14) 46.7 ± 5.8 41.5 ± 5.9 12.9 (6.4 to 20.4)** 0.027  
QQ (11) 11.8 ± 2.6 14.0 ± 3.3 -15.7 (-21.9 to -9.5)* 0.340 R1 0.120 
QR+RR (11) 13.7 ± 2.8 15.8 ± 5.4 -13.3 (-20.9 to -5.7)* 0.022  
LL (8) 13.2 ± 2.8 14.7 ± 7.4 -10.4 (-11.1 to 1.1) 0.029 M1 0.370 
SFA  
(% En) 
LM+MM (14) 12.3 ± 2.9 14.5 ± 3.3 -15.2 (-24.3 to -6.1)* 0.270  
QQ (11) 18.8 ± 3.7 20.7 ± 4.4 -6.5 (-22.1 to 9.0) 0.377 R1 0.785 
QR+RR (11) 19.6± 6.1 19.0 ± 7.8 15.2 (-16.3 to 46.7) 0.303  
LL (8) 20.8 ± 7.2 21.6 ± 8.7 6.8 (-26.8 to 40.6) 0.644 M1 0.133 
MUFA  
(% En) 
LM+MM (14) 18.2± 2.8 19.0 ± 4.0 1.3 (-18.3 to 21.0) 0.830  
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QQ (11) 12.7 ± 2.6 7.3 ± 3.2 111 (62.1 to 160) 0.005 R1 0.817 
QR+RR (11) 13.4 ± 2.9 7.0 ± 3.9 143 (98.1 to 189) 0.004  
LL (8) 12.6 ± 2.2 7.8 ± 4.9 136 (82.2 to 188) 0.035 M1 0.860 
PUFA  
(% En) 
LM+MM (14) 13.3 ± 3.0 6.8 ± 2.5 120 (87.1 to 154) <0.001  
QQ (11) 4.2 ± 0.2 9.6 ± 3.8 -45.8 (-63.8 to -27.8) <0.001 R1 0.754 
QR+RR (11) 4.2 ± 0.4 10.9 ± 3.1 -52.7 (-66.4 to -38.9) <0.001  
LL (8) 4.4 ± 0.4 8.9 ± 3.3 -40.1 (-62.9 to -17.3) 0.004 M1 0.279 
ω-6 PUFA/ 
ω-3 PUFA 
LM+MM (14) 4.2 ± 0.2 10.5 ± 3.5 -54.0 (-66.6 to -41.4) <0.001  
QQ (11) 1.7 ± 4.2 1.2 ± 2.1 446 (-589 to 1481) 0.363 R1 0.889 
QR+RR (11) 1.6 ± 3.1 1.1 ± 2.8 -13.8 (-37.0 to 9.5) 0.213  
LL (8) 0.7 ± 2.0 1.1 ± 3.1 -12.5 (-42.0 to 17.1) 0.351 M1 0.440 
Alcohol  
(% En) 
LM+MM (14) 2.2 ± 4.3 1.1 ± 1.9 380 (-490 to 1251) 0.363  
QQ (11) 378.1 ± 165.1 398.1 ± 135.7 11.6 (-34.7 to 58.1) 0.591 R1 0.262 
QR+RR (11) 362.9 ± 143.3 313.7 ± 128.1 37.9 (-22.9 to 98) 0.192  
LL (8) 378.8 ± 110.2 266.6 ± 85.7 61.0 (-9.5 to 132) 0.080 M1 0.129 
Cholesterol 
(mg) 
LM+MM (14) 366.9 ± 175.4 413.0 ± 132.7 2.2 (-37.1 to 41.4) 0.905  
QQ (11) 14.6 ± 6.0 11.7 ± 4.6 36.0 (-8.7 to 80.9) 0.104 R1 0.746 
QR+RR (11) 13.4± 5.9 14.0 ± 4.7 13.2 (-45.8 to 72.4) 0.624  
LL (8) 13.9 ± 6.6 13.2 ± 4.1 18.0 (-52.6 to 88.6) 0.506 M1 0.874 
Fiber (g) 
LM+MM (14) 14.1 ± 5.6 12.4 ± 5.1 30.1 (-11.8 to 72.0) 0.145  
QQ (11) 15.7 ± 3.7 9.8± 3.8 82.3 (33.6 to 131) 0.003 R1 0.269 
QR+RR (11) 15.0 ± 1.3 8.2± 3.8 120 (50.7 to 190) 0.004  
LL (8) 14.8 ± 1.1 8.7 ± 3.6 94.7 (29.2 to 160) 0.011 M1 0.527 
Total 
tocopherol 
(mg) 
LM+MM (14) 15.7 ± 3.5 9.2 ± 4.0 102 (48.1 to 156) <0.001  
Data are mean values ± standard deviations of volunteers (12 men and 10 women) classified according to their PON-1-55 polymorphism variants. N=number of 
volunteers. SFA: Saturated fatty acids; MUFA: Monounsaturated fatty acids; PUFA: Polyunsaturated fatty acids. The net change (%), mean and 95%CI for each 
variable was calculated taken into account end and baseline of both periods as follow: Net change (%) = (WM-CM)*100/CM. R1, Gen effect QQ vs. QR+RR; M1, Gen 
effect LL vs. LM+MM.  
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Table 3. Body mass index (BMI), lipid, glucose and blood pressure (BP) changes during walnut paste-enriched meat (WM) and low-fat meat (CM) periods 
and whole trial in PON-1 192QQ and QR+RR and PON-1 55LL and LM+MM participants. 
  WM period CM period   
 Carrier (nr) Baseline End Baseline End Net change (%) Mean (95%CI) 
Net change 
(%) (p) 
Gen*treatment 
Interaction1 (p) 
BMI (kg/m2) QQ (11) 30.0 ± 4.0 29.8 ± 4.1 29.8 ± 4.3 29.6 ± 4.3 0.01 (-0.72 to 0.74) 0.981 R1 0.185 
 QR+RR (11) 29.0 ± 2.7 28.9 ± 2.6 29.1 ± 2.9 29.0 ± 3.0 -0.11 (-1.9 to 1.6) 0.890  
 LL (8) 29.3 ± 3.4 29.3 ± 3.2 29.7 ± 3.3 29.7 ± 3.4 0.05 (-2.0 to 2.1) 0.958 M1 0.057 
 LM+MM (14) 29.7 ± 3.7 29.4 ± 3.7 29.4 ± 4.0 29.2 ± 4.1 -0.11 (-0.94 to 0.72) 0.782  
QQ (11) 92.3 ± 9.1 98.3 ± 3.5 94.9 ± 8.5 99.8 ± 8.2 4.2 (-4.2 to 8.4) 0.350 R1 0.617 
QR+RR (11) 94.5 ± 6.6 100.3 ± 10.4 98.8 ± 11.4 99.4 ± 6.8 3.0 (-3.4 to 9.4) 0.322  
LL (8) 98.5 ± 8.3 105.2 ± 8.8 96.3 ± 13.6 100.4 ± 8.6 6.6 (-1.5 to 14.7) 0.095 M1 0.223 
Glucose 
(mg/dl) 
LM+MM (14) 91.6 ± 6.9 95.6 ± 4.8 97.4 ± 7.4 98.4 ± 6.5 2.5 (-1.9 to 6.8) 0.241  
QQ (11) 194.9± 42.8 197.4 ± 40.0 208.3± 47.3 199.2 ± 45.1 8.7 (-4.0 to 21.5) 0.156 R1 0.095 
QR+RR (11) 243.6 ± 41.9 231.1 ± 29.8 241.7 ± 37.5 223.0± 34.5* -1.3 (-25.0 to 22.5) 0.270  
LL (8) 240.1 ± 36.6 238.4 ± 33.5 249.0± 44.8 222.3 ± 34.9+ 10.6 (-8.8 to 30.1) 0.219 M1 0.382 
Cholesterol 
(mg/dl) 
LM+MM (14) 200.5 ± 49.9 195.8 ± 33.4 209.4 ± 41.4 201.2± 43.7 5.7 (-3.7 to 15.0) 0.205  
QQ (11) 42.5 ± 9.8 40.8 ± 8.9 44.2 ± 7.3 39.5 ± 5.2* 8.8 (-4.0 to 21.5) 0.152 R1 0.531 
QR+RR (11) 51.3 ± 11.2 46.3 ± 9.1 47.9 ± 10.9 43.7 ± 6.5 -13 (-25.1 to 22.5) 0.903  
LL (8) 47.4 ± 6.8 45.6 ± 9.7 48.9± 10.2 42.1 ± 5.8* 8.8 (-21.2 to 38.7) 0.487 M1 0.795 
HDL (mg/dl) 
LM+MM (14) 45.7 ± 13.4 41.7 ± 8.9* 44.2 ± 8.2 40.9 ± 6.3+ 1.5 (-12.0 to 14.9) 0.812  
QQ (11) 123.7 ± 31.4 125.0 ± 32.2 137.6 ± 37.0 133.1 ± 37.0 3.3 (-13.3 to 19.9) 0.657 R1 0.547 
QR+RR (11) 161.9 ± 31.4 159.0 ± 18.5 169.1 ± 30.8 159.3 ± 23.1 5.2 (-4.9 to 15.2) 0.264  
LL (8) 155.3 ± 27.2 161.8 ± 19.1 174.8 ± 35.0 164.5 ± 30.6 9.6 (-6.0 to 25.2) 0.176 M1 0.704 
LDL (mg/dl) 
LM+MM (14) 131.4 ± 39.1 126.3 ± 30.5 139.7 ± 33.2 134.7 ± 32.5 1.3 (-11.1 to 13.6) 0.826  
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QQ (11) 143.5 ±.76.3 158.1 ± 63.7 132.8 ±.63.2 155.1 ± 72.1 0.65 (-41.6 to 43.0) 0.972 R1 0.024 
QR+RR (11) 152.1 ± 80.5 129.5 ± 49.1 142.3 ± 64.5 122.4 ± 45.0 -4.5 (-39.8 to 30.8) 0.773  
LL (8) 186.8 ± 70.8 155.3 ± 58.4 155.0 ± 63.7 139.3 ± 72.0 -17.4 (-92.2 to 57.4) 0.577 M1 0.031 
Triglycerides 
(mg/dl) 
LM+MM (14) 122.2 ± 70.7 139.1 ± 59.5 127.8 ± 62.1 142.0 ± 61.4 6.8 (-13.6 to 27.1) 0.476  
QQ (11) 138.3 ± 14.1 137.8 ± 15.8 144.2 ± 20.6 138.8 ± 15.9 4.3 (-5.8 to 14.4) 0.364 R1 0.276 
QR+RR (11) 151.1 ± 28.8 135.3 ± 11.1 147.4 ± 31.8 142.1 ± 26.6 -8.1 (-19.9 to 3.6) 0.152  
LL (8) 160.7 ± 24.5 139.2 ± 7.5* 158.0 ± 30.7 147.6± 27.6 -7.6 (-25.2 to 10.0) 0.340 M1 0.033 
Systolic BP 
(mmHg) 
LM+MM (14) 134.6 ± 15.3 135.2 ± 16.2 138.6± 20.2 135.9 ± 15.6 1.4 (-6.8 to 9.6) 0.725  
QQ (11) 89.2 ± 7.2 87.7 ± 10.7 93.9 ± 11.5 82.7 ± 9.7* 9.5 (2.9 to 16.1) 0.039 R1 0.149 
QR+RR (11) 107.9 ± 34.1 83.6 ± 6.5* 94.2 ± 18.8 86.6 ± 10.0 -18.3 (-36.0 to -0.49) 0.045  
LL (8) 114.5 ± 37.4 85.2 ± 10.8* 102.6 ± 14.0 86.0 ± 10.0 -11.5 (-33.7 to 10.6) 0.257 M1 0.007 
Diastolic BP 
(mmHg) 
LM+MM (14) 89.5 ± 9.1 85.9 ± 8.1 89.1 ± 14.1 83.9 ± 7.3 -0.3 (-13.4 to 12.8) 0.964  
Data are mean values ± standard deviations of volunteers (12 men and 10 women) classified according to their PON-1-192 and PON-1-55 polymorphism variants. N=number 
of volunteers. R1, Gen effect QQ vs. QR+RR; M1, Gen effect LL vs. LM+MM. The net change (%), mean and 95%CI for each variable was calculated taken into account end 
and baseline of both periods as follow: Net change (%) = (WMend-WMbaseline)-(CMend-CMbaseline)*100/CMbaseline. 
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Table 4. Effects of walnut paste-enriched meat (WM), low-fat meat (CM) and the whole trial on erythrocyte reduced glutathione (GSH), oxidized glutathione (GSSG), 
redox index and lipid peroxidation (LPO), and serum γ-tocopherol and α-tocopherol changes in PON-1 192QQ and QR+RR and PON-1 55LL and LM+MM participants. 
 WM period CM period Net change 
(%) (p) 
 
Carrier (nr) 
Baseline End Baseline End 
Net change (%)  
Mean (95%CI) 
 
Gen*treatment 
Interaction1 (p) 
PON-1 192QQ (11) 3.9 ± 1.7 4.7 ± 1.4** 4.3 ± 1.4 4.6 ± 1.3 13.7 (2.9 to 24.6) 0.046 R1 0.830 
PON-1 192QR+RR (11) 3.1 ± 1.2 4.3 ± 1.1* 3.5 ± 0.7 3.8 ± 0.7 11.8 (-23.2 to 46.9) 0.057  
PON-1 55LL (8) 3.6 ± 1. 7 4.3 ± 1.4 3.6 ± 1.3 4.2 ± 1.14* 3.7 (-55.7 to 63.1) 0.869 M1 0.047 
GSH  
(μmol/g Hb) 
PON-1 55LM+MM (14) 3.3 ± 1.5 4.6 ±1.1*** 4.0 ± 1.1 4.1 ± 1.0 19.8 (1.7 to 38.0) 0.001  
PON-1 192QQ (11) 0.6 ± 0.3 1.0 ± 0.3*** 0.7 ± 0.3 0.8 ± 0.3** 48.5 (33.9 to 63.0) 0.001 R1 0.100 
PON-1 192QR+RR (11) 0.6 ± 0.2 0.9 ± 0.3*** 0.5 ± 0.2 0.7 ± 0.3 -36.9 (-161.1 to 87.4) 0.554  
PON-1 55LL (8) 0.7 ±0.2 0.9 ± 0.3** 0.5 ± 0.3 0.7 ± 0.3 -27.6 (-260.7 to 205.5) 0.985 M1 0.072 
GSSG  
(μmol/g Hb) 
PON-1 55LM+MM (14) 0.6 ± 0.2 1.0 ± 0.3*** 0.6 ± 0.3 0.7 ± 0.3* 49.5 (30.4 to 68.6) 0.001  
PON-1 192QQ (11) 7.0 ± 4.2 5.1 ± 2.3* 7.4 ± 3.5 7.2 ± 3.3 -25.7 (-39.3 to -12.1) 0.061 R1 0.044 
PON-1 192QR+RR (11) 5.9 ± 2.9 5.6 ± 2.3 8.2 ± 3.5 6.1 ± 2.7 8.3 (-25.8 to 42.4) 0.202  
PON-1 55LL (8) 5.8 ± 3.1 5.1 ± 2.0 8.2 ± 3.5 6.3 ± 2.5 -1.0 (-59.2 to 37.3) 0.516 M1 0.371 
Redox index1 
PON-1 55LM+MM (14) 6.7 ± 3.8 5.4 ± 2.5 7.6 ± 3.5 6.8 ± 3.3 -17.6 (-43.7 to 8.6) 0.563  
PON-1 192QQ (11) 3.1 ± 2.1 3.1 ± 2.0 2.1 ± 1.3 1.9 ± 1.7 6.9 (-125.3 to 139.1) 0.856 R1 0.045 
PON-1 192QR+RR (11) 4.1 ± 1.1 1.4 ± 1.1** 2.2 ± 1.3 2.1 ± 1.9 -147.9 (-400.0 to 103.8) 0.009  
PON-1 55LL (8) 3.5 ± 1.3 2.1 ± 1.2 1.8 ± 1.0 1.8 ± 2.0 -41.7 (-201.0 to 117.7) 0.208 M1 0.827 
LPO  
(μmol/L) 
PON-1 55LM+MM (14) 3.7 ± 2.1 2.4 ± 2.3 2.4 ± 1.4 2.2 ± 1.3 17.5 (-275.5 to 310.5) 0.368  
PON-1 192QQ (11) 43.2 ± 12.3 48.0 ± 11.7* 41.4 ± 16.8 40.1 ± 16.3 10.9 (-8.0 to 28.9)  0.103 R1 0.086 
PON-1 192QR+RR (11) 41.3 ± 12.1 56.2 ± 27.9* 40.2 ± 13.8 45.1 ± 18.8 29.5 (-6.5 to 63.5) 0.037  
PON-1 55LL (8) 43.6 ± 12.1 48.9 ± 13.3* 42.1 ± 12.9 42.8 ± 16.2 14.7 (-6.8 to 38.8) 0.092 M1 0.641 
γ-tocopherol  
(μg/dL) 
PON-1 55LM+MM (14) 39.7 ± 11.9 53.9 ± 28.8* 38.6 ± 19.3 41.8 ± 22.0 26.1 (-4.1 to 56.2) 0.068  
PON-1 192QQ (11) 1324 ± 261 1387 ± 279 1405 ± 330 1359 ± 250 22.0 (-15.1 to 19.5) 0.735 R1 0.554 
PON-1 192QR+RR (11) 1197 ± 245 1232 ± 255 1321 ± 395 1329 ± 385 -6.1 (-23.2 to 11.0) 0.606  
PON-1 55LL (8) 1331 ± 261 1359 ± 287 1356 ± 438 1312 ± 352 -0.3 (-14.3 to 13.8) 0.857 M1 0.713 
α-tocopherol  
(μg/dL) 
PON-1 55LM+MM (14) 1138 ± 206 1224 ± 239 1368 ± 322 1362 ± 308 -4.9 (-28.7 to 18.9) 0.340  
Values are mean ± SD of volunteers (12 men and 10 women). Number of volunteers for each polymorphism in parenthesis. 1Redox index: GSH/GSSG. Values bearing asterisks (*p < 0.05, **p < 
0.01, ***p < 0.001) differed significantly from their respective baseline values for the same allele and type of meat consumed. The net change (%), mean and 95%CI for each variable was 
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calculated taken into account end and baseline of both periods as follow: Net change (%) = (WMend-WMbaseline)-(CMend-CMbaseline)*100/CMbaseline R1 or M1 treatment effect comparison between R 
and non-R or between M and non-M carriers.  
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Table 5. Effects of walnut-enriched meat (WM), low-fat meat (CM) and the whole trial on catalase, superoxide dismutase (SOD), paraoxonase-1 (PON-1) 
and PON-1/HDL cholesterol in PON-1 192QQ and QR+RR and PON-1 55LL and LM+MM participants. 
 
 Carrier (nr) Walnut-enriched meat (WM) diet Control meat (CM) diet Net change 
(%) (p)  
  Baseline End Baseline End 
Net change (%) 
Mean (95%CI) 
 
Gen*treatment 
Interaction1 (p) 
PON-1 192QQ (11) 141.4 ± 59.0 187.5 ± 74.5** 126.7 ± 24.4 131.3 ± 31.0 36.3 (3.0 to 69.8) 0.014 R1 0.988 
PON-1 192QR+RR (11) 132.9 ± 20.4 165.9 ± 55.0 148.7 ± 36.6 139.7 ± 28.5 22.6 (-14.9 to 60.2) 0.057  
PON-1 55LL (8) 148.9 ± 60.1 191.1 ± 74.8 147.9 ± 39.8 151.3 ± 25.4 28.7 (-24.3 to 81.7) 0.143 M1 0.849 
Catalase  
(U/g Hb) 
PON-1 55LM+MM (14) 130.5 ± 30.8 168.5 ± 59.9** 132.6 ± 27.9 126.6 ± 28.2 45.0 (11.0 to -80.2) 0.007  
         
PON-1 192QQ (11) 2.4 ± 0.6 2.9 ± 0.6*** 2.6 ± 0.6 2.7 ± 0.8 13.1 (-1.7 to 27.9) 0.029 R1 0.450 
PON-1 192QR+RR (11) 2.3 ± 0.7 2.6 ± 0.6 2.6 ± 0.8 2.3 ± 0.8 16.8 (-6.6 to 40.3) 0.015  
PON-1 55LL (8) 2.5 ± 0.7 2.9 ± 0.8* 2.8 ± 0.9 2.6 ± 1.1 26.5 (-5.6 to 58.7) 0.082 M1 0.948 
SOD  
(U/g Hb) 
PON-1 55LM+MM (14) 2.3 ± 0.6 2.6 ± 0.5** 2.4 ± 0.6 2.2 ± 0.6 18.3 (1.8 to 34.7) 0.003  
         
PON-1 192QQ (11) 55.7 ± 18.0 77.3 ± 25.9** 59.5 ± 20.3 49.5 ± 22.1* 72.0 (38.7 to 105.4) 0.001 R1 0.591 
PON-1 192QR+RR (11) 48.6 ± 22.5 76.6 ± 55.3 60.8 ± 27.8 46.5 ± 30.1* 60.0 (-10.9 to 131.0) 0.037  
PON-1 55LL (8) 54.8 ± 22.0 67.7 ± 27.6* 62.0 ± 28.1 48.2 ± 34.9* 48.6 (-3.3 to 100.6) 0.002 M1 0.421 
PON-1  
(U/L) 
PON-1 55LM+MM (14) 50.8 ± 19.5 82.7 ± 48.1* 58.9 ± 21.7 47.9 ± 19.8* 76.9 (-25.2 to 179.0) 0.009  
         
PON-1 192QQ (11) 1.3 ± 0.7 1.7 ± 0.3* 1.3 ± 0.5 1.2 ± 0.5 55.8 (-5.9 to 118) 0.050 R1 0.632 
PON-1 192QR+RR (11) 1.0 ± 0.5 1.7 ± 1.2 1.2 ± 0.6 1.1 ± 0.9 79.4 (-20.6 to 179) 0.045  
PON-1 55LL (8) 1.1 ± 0.5 1.5 ± 0.7* 1.2 ± 0.6 1.1 ± 1.0 50.0 (-30.6 to 131) 0.160 M1 0.594 
PON 1/HDL 
cholesterol 
(U/mg) 
PON-1 55LM+MM (14) 1.2 ± 0.7 1.9 ± 0.8* 1.4 ± 0.5 1.2 ± 0.5 77.4 (0.8 to 154) 0.048  
Values are mean ± SD of volunteers (12 men and 10 women). Number of volunteers for each polymorphism in parenthesis. Values bearing asterisks (*p < 0.05, **p <0.01, ***p <0.001) differed 
significantly from their respective baseline values for the same allele and type of meat consumed. The net change (%) mean and 95%CI for each variable was calculated taken into account end 
and baseline of both periods as follow: Net change (%) = (WMend-WMbaseline)-(CMend-CMbaseline)*100/CMbaseline. R1 or M1 treatment effect comparison between R and non-R or between M and 
non-M carriers.  
 
 
